AstraZeneca’s Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

All NewsJuly 16, 2025

AstraZeneca’s anselamimab missed the main goal in a Phase 3 AL amyloidosis trial but showed promising benefit in a defined patient subgroup.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent